{"id":"W4417530895","doi":"10.1016/j.esmorc.2025.100055","title":"IMMUNOSARC2 (COHORT 7A): A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF EPIRUBICIN AND IFOSFAMIDE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Duke Cancer Institute; National Cancer Institute; Knight Cancer Institute, Oregon Health and Science University; University of Texas MD Anderson Cancer Center; University of California, Irvine; USC Norris Comprehensive Cancer Center; McGill University Health Centre; Huntsman Cancer Institute; McGill University; Royal Marsden NHS Foundation Trust; Medical Center, University of Pittsburgh; University of Pittsburgh; Washington University in St. Louis; Moffitt Cancer Center; Centre Hospitalier Universitaire de Bordeaux; University of Southern California; National Institutes of Health; Ohio State University; Memorial Sloan-Kettering Cancer Center; Children's Hospital of Philadelphia","keywords":"Nivolumab; Ifosfamide; Epirubicin; Sarcoma; First line; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009758482,0.001025065,0.001056573,0.0003520348,0.0002408458,0.0007434142,0.0004563024,0.0005728833,0.002126771],"category_scores_gemma":[0.0003150186,0.000243126,0.0009053408,0.0002326551,0.0003639967,0.0002924,0.0004112909,0.001109313,0.0005873011],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006656376,"about_ca_system_score_gemma":0.0009404093,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001007576,"about_ca_topic_score_gemma":0.003090456,"domain_scores_codex":[0.9998254,0.00006601544,0.000006900083,0.00003580462,0.00002277174,0.00004307743],"domain_scores_gemma":[0.9998385,0.00001466509,0.00002748787,0.0000206044,0.00001598712,0.00008278759],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5511711,0.03000549,0.04388004,0.001795776,0.004031892,0.0008556432,0.0005069857,0.004394105,0.1108016,0.0007658724,0.01213106,0.2396604],"study_design_scores_gemma":[0.3834125,0.418991,0.1394436,0.000200786,0.002646141,0.002419558,0.0002843755,0.003135151,0.02176462,0.0007150287,0.02691631,0.00007092342],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929768,0.001977888,0.0003582041,0.0001815946,0.00005760494,0.0008427328,0.001820507,0.00006974029,0.001714727],"genre_scores_gemma":[0.9741068,0.002152167,0.001950439,0.000900907,0.0001435249,0.001644975,0.01514061,0.00004659822,0.003913893],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002126771,"threshold_uncertainty_score":0.007114828,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02086258826529606,"score_gpt":0.3186337084991464,"score_spread":0.2977711202338503,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}